

PRE-FILLED SYRINGES WILL BE THE PREFERRED CHOICE

By SNS Research

PFS BENEFITS

- Convenience in self-administration
- Elimination of dosing errors
- Decreased needle-stick injuries




INDUSTRY INNOVATION

Drug and pre-filled syringe manufacturers are teaming up as early as Phase I of drug development to ensure efficacy, safety, and end-user preferences.



DRUG CLASS AVAILABILITY IN PFS

- Antibodies
- Fusion Proteins
- Insulin & Diabetes Therapies
- Somatropin
- Interferons
- EPO
- G-CSF
- Antithrombotics
- Vaccines



REVENUE

\$8.1 Billion by the end of 2023

CAGR

11.3% over 2023-2028

[THE PRE-FILLED SYRINGES REPORT 2023](#)

RELEASE DATE: APRIL 2023

NUMBER OF PAGES: 306

Read more at snsintel.com